Cite
MLA Citation
Angela Alistar et al.. “Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.” Lancet oncology, vol. 18, no. 6, n.d., pp. 770–778. http://access.bl.uk/ark:/81055/vdc_100046742673.0x000061